Masthead.
- Published in:
- Clinical Cardiology, 2004, v. 27, n. S1, p. fmi, doi. 10.1002/clc.4960271301
- Publication type:
- Article
Works matching IS 01609289 AND DT 2004 AND VI 27 AND IP S1
Results: 6
1
2
Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles.
- Published in:
- Clinical Cardiology, 2004, v. 27, n. S1, p. 14, doi. 10.1002/clc.4960271305
- By:
- Publication type:
- Article
3
Cardiovascular risk stratification and cardiovascular risk factors associated with erectile dysfunction: Assessing cardiovascular risk in men with erectile dysfunction.
- Published in:
- Clinical Cardiology, 2004, v. 27, n. S1, p. 8, doi. 10.1002/clc.4960271304
- By:
- Publication type:
- Article
4
Role of the cardiologist: Clinical aspects of managing erectile dysfunction.
- Published in:
- Clinical Cardiology, 2004, v. 27, n. S1, p. 3, doi. 10.1002/clc.4960271303
- By:
- Publication type:
- Article
5
Novel phosphodiesterase type 5 inhibitors: Assessing hemodynamic effects and safety parameters.
- Published in:
- Clinical Cardiology, 2004, v. 27, n. S1, p. 20, doi. 10.1002/clc.4960271306
- By:
- Publication type:
- Article
6
Erectile dysfunction and cardiovascular considerations: Managing patients effectively with phosphodiesterase type 5 inhibitors.
- Published in:
- Clinical Cardiology, 2004, v. 27, n. S1, p. 1, doi. 10.1002/clc.4960271302
- By:
- Publication type:
- Article